Biocept, Inc

Biocept, Inc. (Nasdaq: BIOC) develops and performs clinical laboratory tests to help patients with cancer that has metastasized to the central nervous system (CNS). Our CNSideTM assay provides enhanced detection and analysis of tumor cells and cell-free DNA from cerebrospinal fluid (CSF). Quantitative results help evaluate a patients response to treatment. Additional biomarkers can characterize genetic changes associated with therapy resistance and identify new options for treating CNS metastasis. CNSide results from Biocepts CLIA-certified and CAP-accredited laboratory help oncologists manage one of the most difficult complications of cancer, answering three critical questions: Is there tumor in the CSF? Is there...

Oncology testing,ctc testing,ctdna,laboratory testing,cancer diagnostics,clinical testing,liquid biopsy,clinical services,diagnostic products,testing services,cancer diagnostic development,metastatic breast cancer,non-small cell lung cancer,prostate cancer,colorectal cancer,melanoma,gastric cancer,and molecular testing

Biocept, inc operates in the Biotechnology research industry.

Biocept, inc's revenue is 11m - 100m

Biocept, inc has 11 - 50 employees.